MP14-16 EFFICACY OF NIVOLUMAB PLUS IPILIMUMAB IN PRIMARY TUMOR AS FIRST-LINE THERAPY IN THE PATIENTS WITH ADVANCED RENAL CELL CARCINOMA

Authors :: Keita Minami
Akira Kashiwagi
Tango Mochizuki
Satoru Maruyama
Nobuo Shinohara
Takashige Abe
Toru Harabayashi
Ichiro Takeuchi
Haruka Miyata
Riyo Fukui
Hiroshi Kikuchi
Takahiro Osawa
Ryuji Matsumoto
Noboru Yamashita
Ken Morita
Ataru Sazawa
Source :: Journal of Urology. 206
Publication Year :: 2021
Publisher :: Ovid Technologies (Wolters Kluwer Health), 2021.

Subjects :: Oncology
medicine.medical_specialty
business.industry
Urology
Ipilimumab
medicine.disease
Primary tumor
First line therapy
Renal cell carcinoma
Internal medicine
medicine
Nivolumab
business
medicine.drug

Full Text Access

Tools